120 related articles for article (PubMed ID: 8499153)
1. Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
de Forni M; Chabot GG; Armand JP; Fontana X; Recondo G; Domenge C; Carde P; Barbu M; Gouyette A
Eur J Cancer; 1993; 29A(7):983-8. PubMed ID: 8499153
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Burris HA; Raymond E; Awada A; Kuhn JG; O'Rourke TJ; Brentzel J; Lynch W; King SY; Brown TD; Von Hoff DD
Invest New Drugs; 1998; 16(1):19-27. PubMed ID: 9740540
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
Bork E; Vest S; Hansen HH
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1403-11. PubMed ID: 2591433
[TBL] [Abstract][Full Text] [Related]
7. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
Schwartsmann G; van der Vijgh WJ; van Hennik MB; Klein I; Vermorken JB; Dodion P; ten Bokkel Huinink WW; Joggi G; Gall H; Crespeigne N
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1675-81. PubMed ID: 2632251
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
11. Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Schwartsmann G; Bork E; Vermorken JB; Nieboer C; Dodion P; ten Bokkel Huinink WW; Seldenrijk CA; Armand JP; Pinedo HM
Cancer; 1989 Jan; 63(2):243-8. PubMed ID: 2521297
[TBL] [Abstract][Full Text] [Related]
12. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
Urba S; Doroshow J; Cripps C; Robert F; Velez-Garcia E; Dallaire B; Adams D; Carlson R; Grillo-Lopez A; Gyves J
Cancer Chemother Pharmacol; 1992; 31(2):167-9. PubMed ID: 1451236
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
[TBL] [Abstract][Full Text] [Related]
18. Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.
King SY; Agra AM; Shen HS; Chi CL; Adams DB; Currie VE; Bertino JR; Pieniaszek HJ; Quon CY
Cancer Chemother Pharmacol; 1994; 35(2):101-8. PubMed ID: 7987984
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
